Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: genetically modified skin replacement therapy - Stratatech

Next Previous
Drug Profile

Research programme: genetically modified skin replacement therapy - Stratatech

Alternative Names: EpiReady; ExpressGraft™; ExpressGraft™ - Anti-tumour; ExpressGraft™ - Anti-tumour IL-12; ExpressGraft™ - Antineoplastic; ExpressGraft™ - Pro-angiogenic; ExpressGraft™ - Pro-angiogenic VEGF; ExpressGraft™ Enhance

Latest Information Update: 28 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Mallinckrodt plc; Stratatech
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cathecilidin expression stimulants; Gene transference; Interleukin-12 expression stimulants; Tissue replacements; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wounds
  • No development reported Skin cancer; Skin ulcer

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for preclinical development in Skin-cancer(Prevention) in USA (Topical, Patch)
  • 28 Dec 2022 No recent reports of development identified for preclinical development in Skin-ulcer in USA (Topical, Patch)
  • 03 Mar 2020 Preclinical trials in Wounds in USA (Topical) before March 2020 (Mallinckrodt pipeline, April 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top